- Home
- LXEH vs TCRT Comparison
LXEH vs TCRT Comparison
Compare LXEH & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- TCRT
- Stock Information
- Founded
- LXEH 2001
- TCRT 1998
- Country
- LXEH China
- TCRT United States
- Employees
- LXEH N/A
- TCRT N/A
- Industry
- LXEH Other Consumer Services
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- TCRT Health Care
- Exchange
- LXEH Nasdaq
- TCRT Nasdaq
- Market Cap
- LXEH 4.7M
- TCRT 3.8M
- IPO Year
- LXEH 2020
- TCRT N/A
- Fundamental
- Price
- LXEH $3.55
- TCRT $2.00
- Analyst Decision
- LXEH
- TCRT
- Analyst Count
- LXEH 0
- TCRT 0
- Target Price
- LXEH N/A
- TCRT N/A
- AVG Volume (30 Days)
- LXEH 16.4K
- TCRT 33.8K
- Earning Date
- LXEH 09-27-2024
- TCRT 11-14-2024
- Dividend Yield
- LXEH N/A
- TCRT N/A
- EPS Growth
- LXEH N/A
- TCRT N/A
- EPS
- LXEH N/A
- TCRT N/A
- Revenue
- LXEH $5,628,870.00
- TCRT $7,000.00
- Revenue This Year
- LXEH N/A
- TCRT N/A
- Revenue Next Year
- LXEH N/A
- TCRT N/A
- P/E Ratio
- LXEH N/A
- TCRT N/A
- Revenue Growth
- LXEH N/A
- TCRT N/A
- 52 Week Low
- LXEH $1.95
- TCRT $1.63
- 52 Week High
- LXEH $65.06
- TCRT $33.00
- Technical
- Relative Strength Index (RSI)
- LXEH 51.13
- TCRT 43.99
- Support Level
- LXEH $2.26
- TCRT $1.63
- Resistance Level
- LXEH $2.47
- TCRT $2.10
- Average True Range (ATR)
- LXEH 0.13
- TCRT 0.30
- MACD
- LXEH 0.03
- TCRT -0.04
- Stochastic Oscillator
- LXEH 50.10
- TCRT 21.03
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.